Navigation Links
Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone
Date:3/2/2009

RANCHO CORDOVA, Calif., March 2 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading developer and supplier of products that process and store adult stem cells, announced today that products derived from its Intellectual Property have been used to collect, process and store stem cells from cord blood in more than one million procedures since the products were introduced a decade ago. Cord blood stem cells have been used to reconstitute the blood cell forming marrow of patients undergoing treatment for leukemia and lymphoma. Cord blood is also being used in studies regarding treatment for more than 70 genetic diseases and most recently, cerebral palsy.

"The collection and processing of stem cells from cord blood utilizing these products has increased dramatically over the past decade, rising from 5,000 units in 1999 to more than 250,000 units in 2008," said Matthew Plavan, Chief Executive Officer of ThermoGenesis Corp.

These products include:

  • Sterile disposable bag sets used to collect cord blood from the placenta/umbilical cord and other manual disposable bag sets that concentrate the stem cells resident in the cord blood.
  • Novel sterile disposable bag sets that take advantage of the AutoXpress(TM) Platform to harvest and concentrate stem cells through automated means.

"We believe that the ongoing research regarding the therapeutic benefits of stem cells and the likely expansion of financial support for stem cell programs will mandate greater activity in the collection, processing, freezing and storage of cord blood stem cell units in the future," Plavan said.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

  • The BioArchive(R) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of automated devices that includes the AXP and the MarrowXpress and companion sterile blood processing disposable for harvesting stem cells in a closed system. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MarrowXpress is used for isolating stem cells from bone marrow.
  • The CryoSeal(R) FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

                                ThermoGenesis Corp.
                        Web site:http://www.thermogenesis.com
                             Contact: Investor Relations
                                 +1-916-858-5107, or
                                 ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
2. ThermoGenesis Corp. Reports First Quarter 2008 Results
3. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
4. ThermoGenesis Announces Filing of 510(k) Application for MarrowXpress
5. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
6. ThermoGenesis Reports First Quarter 2009 Results
7. ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones
8. ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition
9. ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition
10. ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention
11. Quantum light beams good for fast technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Regular gym ... find themselves having to wait longer to access the treadmills. It’s a predictable trend. ... resolutions to lose weight and get in shape by joining gyms, starting new walking ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers ... the start of Project HoldSpace. Through the partnership, the two organizations seek to ... youth between the ages of 13 and 18. Currently focused on Ohio schools, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
(Date:2/5/2016)... 2016 --> ... that the global active pharmaceuticals ingredients (APIs) market stood ... reach US$185.9 bn by 2020. It is expected to ... 2020. The title of the report is "Active Pharmaceutical ... and by Therapeutic Area) - Global Industry Analysis, Size, ...
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology: